Diabetes - Wiki-Pi

Search Results : Diabetes

Can't find the interaction you're looking for? Try the advanced search

26306 interactions found:

Sort by: Relevance Number of Pathways Number of Drugs Number of Diseases

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel	ATP5MC3 and CTLA4	ATP synthase membrane subunit c locus 3	cytotoxic T-lymphocyte associated protein 4	Formation of ATP by chemiosmotic coupling Cristae formation	Co-stimulation by CD28 Co-inhibition by CTLA4 RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)		Abatacept Ipilimumab Tremelimumab		Graves' disease Allograft rejection Type I diabetes mellitus Hashimoto's thyroiditis
Novel	ANXA11 and MPHOSPH9	annexin A11	M-phase phosphoprotein 9
Novel	EPS8 and ERBB3	EGFR pathway substrate 8, signaling adaptor	erb-b2 receptor tyrosine kinase 3	Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea			Tucatinib		Type I diabetes mellitus Lethal congenital contractural syndrome (LCCS)
Novel	CDK18 and PTPRC	cyclin dependent kinase 18	protein tyrosine phosphatase receptor type C		Phosphorylation of CD3 and TCR zeta chains Other semaphorin interactions Neutrophil degranulation				T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
Novel	CALML3 and IL2RA	calmodulin like 3	interleukin 2 receptor subunit alpha		RAF/MAP kinase cascade RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) Interleukin-2 signaling Interleukin receptor SHC signaling		Denileukin diftitox Aldesleukin Basiliximab Daclizumab Inolimomab Camidanlumab tesirine		Type I diabetes mellitus T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
Novel	CCND2 and ARID5B	cyclin D2	AT-rich interaction domain 5B	Cyclin D associated events in G1 Regulation of RUNX1 Expression and Activity Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity	HDMs demethylate histones			Testicular cancer
Novel	GAK and WFS1	cyclin G associated kinase	wolframin ER transmembrane glycoprotein	Golgi Associated Vesicle Biogenesis Clathrin-mediated endocytosis	XBP1(S) activates chaperone genes Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation	Fostamatinib			Wolfram syndrome (WFS); DIDMOAD syndrome Type II diabetes mellitus
Novel	FGF2 and IL2	fibroblast growth factor 2	interleukin 2	PI3K Cascade PIP3 activates AKT signaling Signaling by activated point mutants of FGFR1 Signaling by activated point mutants of FGFR3 FGFR4 ligand binding and activation FGFR1b ligand binding and activation FGFR3c ligand binding and activation FGFR1c ligand binding and activation FGFR2c ligand binding and activation FGFR2b ligand binding and activation Activated point mutants of FGFR2 Constitutive Signaling by Aberrant PI3K in Cancer POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Syndecan interactions Non-integrin membrane-ECM interactions Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR3 Phospholipase C-mediated cascade; FGFR4 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease FGFRL1 modulation of FGFR1 signaling RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by FGFR2 IIIa TM Formation of intermediate mesoderm Formation of the nephric duct TGFBR3 regulates FGF2 signaling Developmental Lineage of Multipotent Pancreatic Progenitor Cells	RAF/MAP kinase cascade RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) Interleukin-2 signaling Interleukin receptor SHC signaling	Sucralfate Pentosan polysulfate Heparin 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid N,O6-Disulfo-Glucosamine 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid ABT-510	Pseudoephedrine Cefazolin SP4160 N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide 3-Mercapto-1-(1,3,4,9-Tetrahydro-B-Carbolin-2-Yl)-Propan-1-One Methyl (2S)-2-[[2-[(3R)-1-carbamimidoylpiperidin-3-yl]acetyl]amino]-3-[4-(2-phenylethynyl)phenyl]propanoate (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid SP2456 2-[2-(2-Cyclohexyl-2-guanidino-acetylamino)-acetylamino]-N-(3-mercapto-propyl)-propionamide Keyhole limpet hemocyanin Girentuximab TG4010		Graft-versus-host disease Type I diabetes mellitus
Novel	ERBB3 and NR4A1	erb-b2 receptor tyrosine kinase 3	nuclear receptor subfamily 4 group A member 1		AKT phosphorylates targets in the nucleus Nuclear Receptor transcription pathway Constitutive Signaling by AKT1 E17K in Cancer	Tucatinib		Type I diabetes mellitus Lethal congenital contractural syndrome (LCCS)
Novel	ERBB3 and IGFBP6	erb-b2 receptor tyrosine kinase 3	insulin like growth factor binding protein 6		Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	Tucatinib		Type I diabetes mellitus Lethal congenital contractural syndrome (LCCS)
Novel	ERBB3 and IRAK4	erb-b2 receptor tyrosine kinase 3	interleukin 1 receptor associated kinase 4		PIP3 activates AKT signaling MyD88:MAL(TIRAP) cascade initiated on plasma membrane IRAK4 deficiency (TLR5) IRAK4 deficiency (TLR2/4) PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Interleukin-1 signaling TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation MyD88 dependent cascade initiated on endosome MyD88 cascade initiated on plasma membrane	Tucatinib	1-(3-HYDROXYPROPYL)-2-[(3-NITROBENZOYL)AMINO]-1H-BENZIMIDAZOL-5-YL PIVALATE Fostamatinib	Type I diabetes mellitus Lethal congenital contractural syndrome (LCCS)	Defects of toll-like receptor signaling, including the following disease: Il-1 receptor-associated kinase 4 (IRAK-4) deficiency
Novel	ERBB3 and SSR3	erb-b2 receptor tyrosine kinase 3	signal sequence receptor subunit 3		SRP-dependent cotranslational protein targeting to membrane	Tucatinib		Type I diabetes mellitus Lethal congenital contractural syndrome (LCCS)
Novel	NFKBIL1 and NOTCH4	NFKB inhibitor like 1	notch receptor 4		Pre-NOTCH Processing in the Endoplasmic Reticulum Pre-NOTCH Transcription and Translation Pre-NOTCH Processing in Golgi Pre-NOTCH Processing in Golgi Notch-HLH transcription pathway Defective LFNG causes SCDO3 NOTCH4 Intracellular Domain Regulates Transcription NOTCH4 Intracellular Domain Regulates Transcription NOTCH4 Activation and Transmission of Signal to the Nucleus NOTCH4 Activation and Transmission of Signal to the Nucleus Negative regulation of NOTCH4 signaling Negative regulation of NOTCH4 signaling
Novel	SSB and NAT8	small RNA binding exonuclease protection factor La	N-acetyltransferase 8 (putative)	RNA Polymerase III Transcription Termination RNA Polymerase III Abortive And Retractive Initiation	Amyloid fiber formation
Novel	FKBP4 and IL2RA	FKBP prolyl isomerase 4	interleukin 2 receptor subunit alpha	HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Attenuation phase ESR-mediated signaling Estrogen-dependent gene expression Potential therapeutics for SARS	RAF/MAP kinase cascade RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) Interleukin-2 signaling Interleukin receptor SHC signaling		Denileukin diftitox Aldesleukin Basiliximab Daclizumab Inolimomab Camidanlumab tesirine		Type I diabetes mellitus T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
Novel	MYH10 and SERPINF2	myosin heavy chain 10	serpin family F member 2	EPHA-mediated growth cone collapse Sema4D induced cell migration and growth-cone collapse RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases Activate ROCKs RHO GTPases activate PAKs RHO GTPases activate PAKs	Platelet degranulation Dissolution of Fibrin Clot		Ocriplasmin Copper		Alpha-2-plasmin inhibitor (a2-PI) deficiency
Novel	MTHFD1L and ARID1B	methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 like	AT-rich interaction domain 1B	Metabolism of folate and pterines	RMTs methylate histone arginines RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known Regulation of MITF-M-dependent genes involved in pigmentation Regulation of MITF-M-dependent genes involved in pigmentation Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) Formation of the canonical BAF (cBAF) complex Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)
Novel	PRKD1 and RGS1	protein kinase D1	regulator of G protein signaling 1	Sphingolipid de novo biosynthesis	G alpha (q) signalling events G alpha (i) signalling events G alpha (i) signalling events	Bryostatin 1 Fostamatinib
Novel	PRKD1 and YY1	protein kinase D1	YY1 transcription factor	Sphingolipid de novo biosynthesis	Activation of anterior HOX genes in hindbrain development during early embryogenesis UCH proteinases DNA Damage Recognition in GG-NER TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Estrogen-dependent gene expression	Bryostatin 1 Fostamatinib
Novel	TNF and TNXB	tumor necrosis factor	tenascin XB	Transcriptional regulation of white adipocyte differentiation TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR1-mediated ceramide production TNFR2 non-canonical NF-kB pathway Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling TNF signaling Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells)	ECM proteoglycans	Etanercept Adalimumab Infliximab Chloroquine Epinephrine Pseudoephedrine Clenbuterol Pranlukast Amrinone Trichostatin A Afelimomab YSIL6 SD118 PN0621 OMS-103HP Talmapimod VX-702 Atiprimod CRx-139 CYT007-TNFQb Andrographolide Ethyl pyruvate AME-527 PR-104 Plinabulin Dexanabinol Onercept Golimumab Certolizumab pegol Pomalidomide Polaprezinc Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Bryostatin 1 Binimetinib Dilmapimod Glycyrrhizic acid		Graft-versus-host disease Systemic lupus erythematosus Allograft rejection Asthma	Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)